These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31277827)

  • 21. The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand.
    Teerawattananon Y; Tritasavit N; Suchonwanich N; Kingkaew P
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):397-404. PubMed ID: 25444298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of coverage with evidence development for medical technologies in Switzerland from 1996 to 2012.
    Brügger U; Ruckstuhl A; Horisberger B; Gratwohl A
    Int J Technol Assess Health Care; 2014 Jul; 30(3):253-9. PubMed ID: 25100035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The 'Myozyme' decision of the Federal Supreme Court of Switzerland and German Law: a constitutional rights and health insurance law perspective].
    Huster S; Bohmeier A
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(6):443-8. PubMed ID: 22857732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health technology assessment in Australia: a role for clinical registries?
    Scott AM
    Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously?
    Franken M; Koopmanschap M; Steenhoek A
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):383-9. PubMed ID: 25444296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medicare and cost-effectiveness analysis.
    Neumann PJ; Rosen AB; Weinstein MC
    N Engl J Med; 2005 Oct; 353(14):1516-22. PubMed ID: 16207857
    [No Abstract]   [Full Text] [Related]  

  • 27. Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity?
    Menon D; Stafinski T; Dunn A; Short H
    Patient; 2015 Feb; 8(1):29-39. PubMed ID: 25516506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How to integrate research evidence on patient preferences in pharmaceutical coverage decisions and clinical practice guidelines: A qualitative study among Dutch stakeholders.
    Utens CM; Dirksen CD; van der Weijden T; Joore MA
    Health Policy; 2016 Jan; 120(1):120-8. PubMed ID: 26563630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Costs and benefits of improving access to psychotherapies for common mental disorders.
    Dezetter A; Briffault X; Ben Lakhdar C; Kovess-Masfety V
    J Ment Health Policy Econ; 2013 Dec; 16(4):161-77. PubMed ID: 24526585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developing a multi-criteria approach for drug reimbursement decision making: an initial step forward.
    Dionne F; Mitton C; Dempster B; Lynd LD
    J Popul Ther Clin Pharmacol; 2015; 22(1):e68-77. PubMed ID: 25715383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa®) in Sweden.
    Willis M; Persson U; Zoellner Y; Gradl B
    Appl Health Econ Health Policy; 2010; 8(6):377-86. PubMed ID: 21043539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Value of Decision Analytical Modeling in Surgical Research: An Example of Laparoscopic Versus Open Distal Pancreatectomy.
    Tax C; Govaert PHM; Stommel MWJ; Besselink MGH; Gooszen HG; Rovers MM
    Ann Surg; 2019 Mar; 269(3):530-536. PubMed ID: 29099396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [IGeL - a questionable debate].
    Schaefer C
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(7):540-1. PubMed ID: 22981030
    [No Abstract]   [Full Text] [Related]  

  • 35. Piloting the development of a cost-effective evidence-informed clinical pathway: managing hypertension in Jordanian primary care.
    Chalkidou K; Lord J; Obeidat NA; Alabbadi IA; Stanley AG; Bader R; Momani A; O'Mahony RM; Qatami L; Cutler D
    Int J Technol Assess Health Care; 2011 Apr; 27(2):151-8. PubMed ID: 21473813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coverage with evidence development: ethical issues and policy implications.
    Miller FG; Pearson SD
    Med Care; 2008 Jul; 46(7):746-51. PubMed ID: 18580395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Legislations and policies to expand mental health and substance abuse benefits in health insurance plans: a community guide systematic economic review.
    Jacob V; Qu S; Chattopadhyay S; Sipe TA; Knopf JA; Goetzel RZ; Finnie R; Thota AB;
    J Ment Health Policy Econ; 2015 Mar; 18(1):39-48. PubMed ID: 25862203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviews.
    Bishop D; Lexchin J
    BMC Health Serv Res; 2013 Mar; 13():88. PubMed ID: 23497271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
    Nicod E
    Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Similarities and differences between five European drug reimbursement systems.
    Franken M; le Polain M; Cleemput I; Koopmanschap M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):349-57. PubMed ID: 22989410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.